First Eagle Investment Management LLC cut its position in Hinge Health Inc. (NYSE:HNGE - Free Report) by 70.0% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 258,184 shares of the company's stock after selling 602,100 shares during the quarter. First Eagle Investment Management LLC owned about 0.32% of Hinge Health worth $25,106,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. SBI Securities Co. Ltd. lifted its holdings in Hinge Health by 39.5% in the third quarter. SBI Securities Co. Ltd. now owns 364 shares of the company's stock worth $35,000 after purchasing an additional 103 shares during the period. ProShare Advisors LLC grew its position in Hinge Health by 2.1% in the 3rd quarter. ProShare Advisors LLC now owns 5,588 shares of the company's stock valued at $543,000 after buying an additional 117 shares in the last quarter. IFP Advisors Inc grew its position in Hinge Health by 140.0% in the 2nd quarter. IFP Advisors Inc now owns 324 shares of the company's stock valued at $27,000 after buying an additional 189 shares in the last quarter. Nykredit A S acquired a new position in Hinge Health during the 2nd quarter valued at about $29,000. Finally, Allworth Financial LP increased its stake in Hinge Health by 402.3% during the 3rd quarter. Allworth Financial LP now owns 437 shares of the company's stock valued at $42,000 after buying an additional 350 shares during the period.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on HNGE shares. Citizens Jmp upped their price target on shares of Hinge Health from $96.00 to $107.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 5th. Stifel Nicolaus raised their price objective on shares of Hinge Health from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Tuesday, November 3rd. Zacks Research upgraded shares of Hinge Health from a "hold" rating to a "strong-buy" rating in a research note on Friday, November 6th. Evercore restated an "outperform" rating and issued a $105.00 target price on shares of Hinge Health in a research report on Wednesday, August 5th. Finally, Morgan Stanley increased their price target on Hinge Health from $117.00 to $131.00 and gave the company an "overweight" rating in a research note on Tuesday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $118.93.
Check Out Our Latest Analysis on HNGE
Insider Buying and Selling
In other news, CEO Daniel Perez sold 4,100 shares of the business's stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $100.20, for a total transaction of $410,820.00. Following the sale, the chief executive officer directly owned 4,100 shares of the company's stock, valued at $410,820. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Budge sold 35,907 shares of the business's stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $121.62, for a total value of $4,367,009.34. Following the sale, the chief financial officer directly owned 256,207 shares in the company, valued at $31,159,895.34. This trade represents a 12.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,260,488 shares of company stock valued at $124,481,770. 18.92% of the stock is owned by insiders.
Hinge Health Trading Down 5.5%
NYSE:HNGE opened at $114.57 on Wednesday. The company has a 50-day moving average of $104.83 and a 200-day moving average of $71.62. The firm has a market cap of $9.31 billion, a price-to-earnings ratio of 65.92, a price-to-earnings-growth ratio of 1.71 and a beta of 1.19. Hinge Health Inc. has a twelve month low of $30.08 and a twelve month high of $126.40.
Hinge Health (NYSE:HNGE - Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.27 by $0.44. The business had revenue of $234.97 million during the quarter. Hinge Health had a net margin of 21.02% and a return on equity of 66.96%. The firm's revenue for the quarter was up 52.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.02) earnings per share. On average, research analysts forecast that Hinge Health Inc. will post 1.56 earnings per share for the current year.
Hinge Health Company Profile
(
Free Report)
Hinge Health is a digital health company focused on musculoskeletal care, including support for people with back, joint and muscle pain. Its services are designed to help members manage conditions through personalized, technology-enabled care. The company's offerings include app-based exercise therapy, education and behavioral support, along with access to clinical care teams. Hinge Health also uses wearable motion sensors in some programs to guide and track exercises. Founded in 2015, Hinge Health primarily provides its services through employers and health plans.
See Also
Want to see what other hedge funds are holding HNGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hinge Health Inc. (NYSE:HNGE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.